Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP- binding site TKI with discontinuation due to treatment failure, warning or intolerance. (2L patient cohort). In addition, newly diagnosed CML-CP patients who may have received up to 4 weeks of prior TKI are included in a separate 1L patient cohort.
Epistemonikos ID: a96c117abd6818f0f59225542e4c88ddd264efd9
First added on: May 13, 2024